Clostridium difficile infection and inflammatory bowel disease: understanding the evolving relationship
- PMID: 20954275
- PMCID: PMC2957597
- DOI: 10.3748/wjg.v16.i39.4892
Clostridium difficile infection and inflammatory bowel disease: understanding the evolving relationship
Abstract
Clostridium difficile (C. difficile) infection (CDI) is the leading identifiable cause of antibiotic-associated diarrhea. While there is an alarming trend of increasing incidence and severity of CDI in the United States and Europe, superimposed CDI in patients with inflammatory bowel disease (IBD) has drawn considerable attention in the gastrointestinal community. The majority of IBD patients appear to contract CDI as outpatients. C. difficile affects disease course of IBD in several ways, including triggering disease flares, sustaining activity, and in some cases, acting as an "innocent" bystander. Despite its wide spectrum of presentations, CDI has been reported to be associated with a longer duration of hospitalization and a higher mortality in IBD patients. IBD patients with restorative proctocolectomy or with diverting ileostomy are not immune to CDI of the small bowel or ileal pouch. Whether immunomodulator or corticosteroid therapy for IBD should be continued in patients with superimposed CDI is controversial. It appears that more adverse outcomes was observed among patients treated by a combination of immunomodulators and antibiotics than those treated by antibiotics alone. The use of biologic agents does not appear to increase the risk of acquisition of CDI. For CDI in the setting of underlying IBD, vancomycin appears to be more efficacious than metronidazole. Randomized controlled trials are required to clearly define the appropriate management for CDI in patients with IBD.
Figures


Similar articles
-
Clostridium difficile and inflammatory bowel disease: role in pathogenesis and implications in treatment.World J Gastroenterol. 2013 Nov 21;19(43):7577-85. doi: 10.3748/wjg.v19.i43.7577. World J Gastroenterol. 2013. PMID: 24282348 Free PMC article. Review.
-
Colon Surgery Risk With Corticosteroids Versus Immunomodulators or Biologics in Inflammatory Bowel Disease Patients With Clostridium difficile Infection.Inflamm Bowel Dis. 2019 Feb 21;25(3):610-619. doi: 10.1093/ibd/izy291. Inflamm Bowel Dis. 2019. PMID: 30260451 Free PMC article.
-
Clostridium Difficile Infection from a Surgical Perspective.J Gastrointest Surg. 2015 Jul;19(7):1363-77. doi: 10.1007/s11605-015-2785-4. Epub 2015 Apr 28. J Gastrointest Surg. 2015. PMID: 25917533 Review.
-
Managing Clostridium difficile in inflammatory bowel disease (IBD).Curr Gastroenterol Rep. 2014;16(7):393. doi: 10.1007/s11894-014-0393-1. Curr Gastroenterol Rep. 2014. PMID: 24838421 Review.
-
Clostridium difficile infection and treatment in the pediatric inflammatory bowel disease population.J Pediatr Gastroenterol Nutr. 2011 Apr;52(4):437-41. doi: 10.1097/MPG.0b013e3181f97209. J Pediatr Gastroenterol Nutr. 2011. PMID: 21407116 Free PMC article.
Cited by
-
Clostridioides difficile Infection in Inflammatory Bowel Disease Patients: A Systematic Review of Risk Factors and Approach in Management.Cureus. 2023 Aug 8;15(8):e43134. doi: 10.7759/cureus.43134. eCollection 2023 Aug. Cureus. 2023. PMID: 37692651 Free PMC article. Review.
-
Microbiota dynamics in patients treated with fecal microbiota transplantation for recurrent Clostridium difficile infection.PLoS One. 2013 Nov 26;8(11):e81330. doi: 10.1371/journal.pone.0081330. eCollection 2013. PLoS One. 2013. PMID: 24303043 Free PMC article.
-
Drug Targeting of Inflammatory Bowel Diseases by Biomolecules.Nanomaterials (Basel). 2021 Aug 10;11(8):2035. doi: 10.3390/nano11082035. Nanomaterials (Basel). 2021. PMID: 34443866 Free PMC article. Review.
-
Clostridium difficile infection aggravates colitis in interleukin 10-deficient mice.World J Gastroenterol. 2014 Dec 7;20(45):17084-91. doi: 10.3748/wjg.v20.i45.17084. World J Gastroenterol. 2014. PMID: 25493020 Free PMC article.
-
Serum procalcitonin levels associate with Clostridioides difficile infection in patients with inflammatory bowel disease.BMC Infect Dis. 2021 Oct 26;21(1):1103. doi: 10.1186/s12879-021-06804-2. BMC Infect Dis. 2021. PMID: 34702217 Free PMC article.
References
-
- Bartlett JG, Chang TW, Gurwith M, Gorbach SL, Onderdonk AB. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med. 1978;298:531–534. - PubMed
-
- McDonald LC, Killgore GE, Thompson A, Owens RC Jr, Kazakova SV, Sambol SP, Johnson S, Gerding DN. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005;353:2433–2441. - PubMed
-
- Kazakova SV, Ware K, Baughman B, Bilukha O, Paradis A, Sears S, Thompson A, Jensen B, Wiggs L, Bessette J, et al. A hospital outbreak of diarrhea due to an emerging epidemic strain of Clostridium difficile. Arch Intern Med. 2006;166:2518–2524. - PubMed
-
- O'Brien JA, Lahue BJ, Caro JJ, Davidson DM. The emerging infectious challenge of clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol. 2007;28:1219–1227. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical